ScanGrants is a public service listing of grants and other funding types to support health research, programs and scholarship.
5 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Call for Applications: National Niemann-Pick Disease Foundation Edward H. Schuchman Research Fellowship
The National Niemann-Pick Disease Foundation (NNPDF) invites applications for research fellowships examining the biology of Acid Sphingomyelinase Deficiency (ASMD; i.e., Types A and B Niemann-Pick Disease), a rare inherited lysosomal storage disease for which there are no effective therapies.
Those eligible to apply for funding are:
• Predoctoral students with a lab selected and an approved thesis
• M.D., Ph.D and D.V.M postdoctoral researchers
• Early career investigators
Preference will be given to research projects that will improve our understanding of the biology and pathogenesis of ASMD. Preference also will be given to research projects developing new therapies for ASMD and for identifying biomarkers to improvide diagnosis and/or to monitor disease progression and efficacy in clinical trials.
The NNPDF Fellowships provide support of $50,000 per annum for two years ($30,000 per annum for three years for predoctoral fellowships) and are renewable based on performance. Applicants must be currently associated with a recognized laboratory.
This fellowship is named for Edward H. Schuchman, Ph.D. a pioneer in ASMD research, and supporter of those affected by Niemann-Pick Disease.
Applications are due May 1st, 2014, and should be submitted by email to the Research Committee Chair. Applicants will be informed of the funding decision by September 1st, 2014, via email. Fellowships awarded will begin October 1st, 2014.
For further information please contact the National Niemann-Pick Disease Foundation's Central Office.
Call for Applications: American Gastroenterological Association-Aptalis Research Award in Pancreatic Disease
Eligibility: Young Investigators
Duration: Two years
Deadline: June 6, 2014
Start Date: Oct. 1, 2014
This award provides $50,000 per year for two years (total $100,000) to young investigators, instructors, research associates or equivalents interested in the function and disorders of the exocrine pancreas. Research topics suitable for funding under this grant include but are not limited to: pancreatitis, pancreatic cancer, pancreatic insufficiency, the gut microbiome-pancreas relationship, pancreatic disease epidemiology or genetics (excluding diabetes), and pancreatic disease biomarkers.
The overall objective of this career development award is to encourage and support research into exocrine pancreatic disorders by helping to sustain the careers of young investigators with an interest in pancreatic disease.
• Candidates for this award must hold an MD, PhD or equivalent degree (e.g., MB, ChB, MBBS, DO) and a full-time faculty position at a North American institution by June 1, 2014.
• AGA membership is required at the time of application submission. Please visit the membership page or call 301-654-2055, extension 651, for membership information.
• The award is intended to support young faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research. Candidates should be in the beginning years of their careers; therefore, established investigators are not appropriate candidates.
• MD applicants: no more than seven years shall have elapsed following the completion of clinical training (GI fellowship or its equivalent) and the start date of this award.
• PhD applicants: no more than seven years shall have elapsed following the awarding of a PhD and the start date of this award.
• Women and underrepresented minority applicants are strongly encouraged to apply; these applications in particular will receive the review committee’s full consideration.
• An appropriately documented parental leave of absence will not be counted toward the above noted seven-year eligibility criteria. Exceptional circumstances may also be considered.
• All submissions must be relevant to diagnosing, treating or researching the functions or diseases of the exocrine pancreas.
• At the time of application submission, candidates may not hold or have held an NIH R01, R29, R21, K08, K23, Veterans Affairs Career Development Award or any award with similar objectives from non-federal sources (such as the American Liver Foundation, Burroughs Wellcome Fund, Crohn’s and Colitis Foundation of America, Robert Wood Johnson Foundation, etc.). Candidates with an active K12 may apply.
• The intent of this award is to foster the scientific independence of junior investigators. It is understood that there may be some overlap with work funded by the mentor, but the goal of this grant is to enable the junior investigator to develop their own research program. It also must be clearly stated that the work submitted by the applicant is primarily that of the applicant, and any work or data from the senior mentor’s laboratory clearly defined.
• Resources allocated through this award are intended to support the career development of the applicant. Accordingly, requests for salary, fringe benefits or other support for the mentor are not allowed. Indirect costs are not allowed. Upon notification of receipt of this award, the recipient must provide institutional approval from the appropriate committee for use of human subjects or animals. If approval is not necessary, the recipient must provide an explanation. Evidence for developing independence in research initiatives should be provided.
• Candidates are required to have a sponsor and preceptor for the award; however, one individual may serve in the capacity of both positions. A sponsor is an individual who takes responsibility for the quality assessment of the proposed research project, the quality of the research environment within which the project will be undertaken, and the experience and expertise of the principal investigator and other key researchers involved. A preceptor will supervise the principal investigator’s research activities and will serve as a mentor.
• Annually, a one-page plain language progress report, a scientific progress report, a financial statement, a list of publications based on the research and a letter of certification from the division chief or department chair, must be submitted by the award recipient by Nov. 30. Second year funding is contingent upon submission of this documentation. All publications, presentations and abstracts arising from work funded by this program must acknowledge support of the AGA-Aptalis Research Award in Pancreatic Disease.
There must be a strong commitment from the candidate’s institution to support the required protected time for research and adequate laboratory space and/or other supporting facilities. These commitments must be outlined in a letter from the candidate’s division chief or department chair. The letter must certify that the award is being used to provide protected time, in accord with the terms of the award. In addition, it is expected that the sponsor will outline specific plans for the future development of the candidate’s research career. The institution must commit to ensuring timely and accurate reporting of the awardee’s current and future research activities at the institution; this is to include an annual report of the funding status, grants submitted and pending, and all publications.
The recipient will be selected based on the following criteria: significance, investigator, innovation, approach, environment, relevance to AGA’s mission and evidence of institutional commitment. The candidate should state clearly how the additional training will benefit his/her research career.
A selection committee comprised of members of the AGA Research Awards Panel will review the proposals and select the award recipients. Funding will commence October 2014.
The application deadline is June 6, 2014. The completed application, letters of support or commitment and other documents, as applicable, must be combined into and submitted as one PDF document. The document must be titled by the applicant’s last name and first initial only. Hard copies are not accepted. Please email the application document to email@example.com. Direct all questions to the research awards manager via telephone at 301-222-4012 or email at firstname.lastname@example.org.
Funding for this award is provided by Aptalis Pharma US, Inc.
Call for Early Career Investigator Travel Fellowship Applications: Companion Diagnostics: From Biomarker Identification to Market Entry
April 28 - 29, 2014 The New York Academy of Sciences
Presented by The New York Academy of Sciences
The recent growth in complex biological data has enabled a major paradigm shift in healthcare away from "one-size-fits-all" approaches towards customized, patient-tailored therapies. Biomarker-based companion diagnostics (CDx), designed to identify responsive patient sub-populations or those likely to experience adverse drug effects, lie at the heart of this personalized, precision medicine movement.
This 2-day conference will provide a neutral forum for international scientists and clinicians from academia, industry, and government — as well as healthcare policy makers, regulatory experts, insurance sector representatives, and other stakeholders — to discuss research, financial, and regulatory strategies that will facilitate CDx development and integration into clinical care. Presentations will illustrate successes and failures based on case studies; evaluate emerging applications of technologies such as epigenetics, bioinformatics, and nanotechnology; analyze diverse therapeutic target areas beyond cancer including inflammatory, infectious, cardiovascular, metabolic, and neurodegenerative diseases; recognize regulatory hurdles; and formulate solutions to better improve public health with CDx and personalized medicine.
The deadline for submission of applications is Friday, March 14, 2014.
Applications are invited from qualified early career investigators. For detailed information on eligibility and application instructions, please send an email to CDx2014@nyas.org with the words "Fellowship Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Please call 212.298.8618 with any questions.
Call for Early Career Investigator and Underrepresented Minority Travel Fellowship Applications: Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
June 19 - 20, 2014 The New York Academy of Sciences
A decade after the first cancer drug targeting VEGF signaling in tumor blood vessel formation received approval by the US Food and Drug Administration (FDA), significant effort has been dedicated toward progressing the research, development, and clinical application of anti-angiogenic cancer therapies. Drawing on lessons learned from successes and failures, this conference will examine ways to improve cancer therapy by addressing urgent issues such as:
i. inherent /acquired resistance,
iii. enhanced invasiveness / metastasis, and
iv. lack of validated predictive and prognostic biomarkers.
Presentations, including a keynote lecture by Harold F. Dvorak, MD, will explore VEGF-dependent and alternative mechanisms of angiogenesis. “Point–Counterpoint” debates between leading experts will aim to resolve controversies regarding the function of vascular normalization, treatment-induced metastasis, and the validity of hypertension as a physiological biomarker.
The deadline for submission of applications is Friday, April 4, 2014.
Applications are invited from qualified early career investigators and early career investigators from underrepresented minorities. For detailed information on eligibility and application instructions, please send an email to Angiogenesis2014@nyas.org with the words "Fellowship Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Please call 212.298.8698 with any questions.
Friedreich's Ataxia Research Alliance Phillip Bennett and Kyle Bryant Translational Research Award
FARA accepts LOIs focusing on pre-clinical and clinical investigations that will advance treatments for FA.
The specific aims must target one or more of the following:
Identification of biomarkers for FA that will elucidate disease variability, severity, and prognosis; facilitate drug screening, and/or optimize selection of patients and clinical endpoints for clinical trials;
Development of tools and technologies that can (a) be directly used for therapy development; (b) overcome existing obstacles to treatment and (c) be directly applied to, or adapted for, delivery of potential therapeutics;
Pre-clinical development and testing of potential therapeutics, biologics, and devices in cells and animals;
Clinical studies of patient outcome measures, potential interventions, or devices.
The deadline for the LOI is May 15. For those invited to submit a full application, the deadline for submission is July 15. On the Main Grant Page, put “PB and KB Translational Award” in the “Grant Type” field. The applicant may request a budget of up to $250,000 per year for one or two years.